Shanghai ZuanZhi Biotechnology

Shanghai ZuanZhi Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of next-generation small molecule drugs. The company focuses on targeting historically undruggable oncogenic drivers, particularly within the RAS/MAPK signaling pathway. Its lead programs include potent and selective inhibitors of KRAS mutations, such as KRAS G12D and G12V, aimed at treating various solid tumors. ZuanZhi utilizes a proprietary structure-based drug design platform to accelerate the discovery of high-affinity candidates. Supported by leading venture capital firms, the company aims to provide transformative therapies for cancer patients globally.